May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Effects of Topical Anti-Glaucoma Medications on Ocular Surface as Evaluated by Gene Expression Pattern
Author Affiliations & Notes
  • Y. Okada
    Wakayama Medical University, Wakayama, Japan
    Department of Ophthalmology,
  • S. Saika
    Wakayama Medical University, Wakayama, Japan
    Department of Ophthalmology,
  • T. Ueyama
    Wakayama Medical University, Wakayama, Japan
    Department of Anatomy,
  • K. Shirai
    Wakayama Medical University, Wakayama, Japan
    Department of Ophthalmology,
  • O. Yamanaka
    Wakayama Medical University, Wakayama, Japan
    Department of Ophthalmology,
  • Y. Ohnishi
    Wakayama Medical University, Wakayama, Japan
    Department of Ophthalmology,
  • P. S. Reinach
    Department of Biological Sciences, State University of New York College of Optometry, Wakayama, New York
  • Footnotes
    Commercial Relationships Y. Okada, None; S. Saika, None; T. Ueyama, None; K. Shirai, None; O. Yamanaka, None; Y. Ohnishi, None; P.S. Reinach, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4814. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Okada, S. Saika, T. Ueyama, K. Shirai, O. Yamanaka, Y. Ohnishi, P. S. Reinach; Effects of Topical Anti-Glaucoma Medications on Ocular Surface as Evaluated by Gene Expression Pattern. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4814.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To examine the expression pattern of stress-related genes, c-fos and c-jun, both the major components of AP-1, and cyclooxygenase-2 (COX-2) in rat ocular surface treated with topical anti-glaucoma medications and benzalkonium chloride preservative.

Methods:: Fifty-two male Wistar rats were used. Anti-glaucoma medications (0.5% timolol, 0.005% latanoprost or 0.12% unoprostone), chemical constituent or benzalkonium chloride preservative (0.005%, 0.01% or 0.02%) were topically applied on the one eye of each animal. The eyes were enucleated after various intervals. In situ hybridization and immunohistochemistry were employed to detect expression of c-fos, c-jun and COX-2.

Results:: Expression of c-fos, c-jun and COX-2 was minimally observed in an uninjured rat corneal epithelium. Thirty to 60 min after applying these all anti-glaucoma medications, signals for c-fos and c-jun mRNAs were detected in the corneal epithelium. Thirty to 60 min after applying 0.005% latanoprost or 0.12% unoprostone, but not timolol, signal for COX-2 were detected in corneal and conjunctival epithelium. Expression of c-fos and c-jun seemed more marked with prostaglandins as compared with timolol. Thirty to 60 min after dropping 0.02% benzalkonium chloride preservative, signals for c-fos and c-jun mRNAs were detected in the conjunctival epithelium. Signal for COX-2 was not induced by applying 0.5%timolol or benzalkonium chloride preservative. Signal for these mRNAs were not affected by applying 0.005% or 0.01% benzalkonium chloride preservative. Proteins of these components were also detected, indicating that each mRNA expression was followed by protein synthesis.

Conclusions:: Corneal and conjunctival epithelial cells are transiently transcriptionally activated at a very early phase following topical administration of anti-glaucoma medications and benzalkonium chloride preservative. Stimulatory effects of prostaglandins on corneal epithelial cells seemed more marked as compared with timolol. Expression of COX-2 may potentially involve in inflammatory response in corneal epithelium.

Keywords: drug toxicity/drug effects • cornea: epithelium • conjunctiva 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×